Pulmonx Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LUNG research report →
About the company
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System.
- CEO
- Glendon E. French
- IPO
- 2020
- Employees
- 291
- HQ
- Redwood City, CA, US
Price Chart
- Market Cap
- $58.71M
- P/E
- -1.07
- P/S
- 0.66
- P/B
- 1.27
- EV/EBITDA
- -1.11
- Div Yield
- 0.00%
- Gross Margin
- 75.49%
- Op Margin
- -58.79%
- Net Margin
- -60.09%
- ROE
- -92.94%
- ROIC
- -50.83%
- Revenue
- $90.50M · 8.01%
- Net Income
- $-54,003,000 · 4.24%
- EPS
- $-1.33 · 7.64%
- Op Income
- $-53,663,000
- FCF YoY
- 0.26%
- 52W High
- $3.88
- 52W Low
- $1.13
- 50D MA
- $1.38
- 200D MA
- $1.64
- Beta
- 0.28
- Avg Volume
- 485.63K
Get TickerSpark's AI analysis on LUNG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 26 | Burns Thomas William | other | 40,000 |
| Jun 5, 26 | Ferrari Richard | other | 40,000 |
| Jun 5, 26 | Florin Daniel P | other | 40,000 |
| Jun 5, 26 | Melenikiotou Georgia | other | 40,000 |
| Jun 5, 26 | Sullivan Tiffany | other | 40,000 |
| Jun 5, 26 | Mead Dana G Jr. | other | 40,000 |
| Mar 2, 26 | Radhakrishnan Srikanth | other | 175,000 |
| Mar 2, 26 | Radhakrishnan Srikanth | sell | 756 |
| Mar 2, 26 | Radhakrishnan Srikanth | sell | 3,068 |
| Mar 2, 26 | Radhakrishnan Srikanth | sell | 2,461 |
Our LUNG coverage
Recent articles, reports, and earnings notes.
No research on LUNG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LUNG report →Similar companies
Peers in the same neighborhood.